share_log

HC Wainwright & Co. Initiates Coverage On Akari Therapeutics With Buy Rating, Announces Price Target of $1.5

HC Wainwright & Co. Initiates Coverage On Akari Therapeutics With Buy Rating, Announces Price Target of $1.5

HC Wainwright&Co.以買入評級啟動對Akari治療公司的報道,宣佈目標價為1.5美元
Benzinga Real-time News ·  2022/12/05 19:10

HC Wainwright & Co. analyst Sean Lee initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $1.5.

HC Wainwright&Co.分析師肖恩·李以買入評級啟動對阿卡里治療公司(納斯達克:AKTX)的報道,並宣佈目標價為1.5美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論